A 60-year-old woman trying to discontinue hormone replacement therapy

JAMA

Volumn 287, Issue 16, 2002, Pages 2130-2137

  Grady, Deborah ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ESTROGEN; RALOXIFENE; TAMOXIFEN;

ADULT; BREAST CANCER; CANCER MORTALITY; CANCER RISK; CASE REPORT; CONFERENCE PAPER; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR;

EID: 0037165669     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.16.2130     Document Type: Conference Paper

References (71)

1. Postmenopausal hormone therapy increases risk for venous thromboembolic disease
2. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease
3. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
4. Oral estrogen replacement therapy versus placebo for hot flushes: A systematic review
5. Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
6. Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials
7. NAMS-Gallup survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy
8. Climacteric symptoms among women aged 60-62 in Linkoping, Sweden, in 1986
9. Megestrol acetate for the prevention of hot flashes
10. Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial
11. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors
12. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program Study
13. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients
14. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate
15. Adverse events reported by postmenopausal women in controlled trials with raloxifene
16. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
17. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy
18. Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression
19. Sex steroids and affect in the surgical menopause: A double blind cross-over study
20. Symptom relief and side effects of postmenopausal hormones: Results from the Postmenopausal Estrogen/Progestin Interventions Trial
21. Hot flashes: Epidemiology and physiology
22. Osteoporosis: An overview of the National Osteoporosis Foundation clinical practice guideline
23. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
24. Does postmenopausal hormone therapy cause breast cancer?
25. Estrogen replacement therapy and fractures in older women
26. Hormone therapy to prevent disease and prolong life in postmenopausal women
27. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease
28. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
29. The protective effects of estrogen on the cardio-vascular system
30. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys
31. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
32. Effects of estrogen replacement on the progression of coronary artery atherosclerosis
33. A clinical trial of estrogen-replacement therapy after ischemic stroke
34. Raloxifene and cardiovascular events in osteoporotic postmenopausal women
35. Hormone replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association
36. Postmenopausal hormone therapy and risk of stroke
37. Postmenopausal estrogen and prevention bias
38. Prior to use of estrogen replacement therapy, are users healthier than nonusers?
39. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project
40. The relationship of treatment adherence to the risk of death after myocardial infarction in women
41. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/ progestin Replacement Study (HERS)
42. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures
43. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis
44. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures
45. Effect of risedronate on the risk of hip fracture in elderly women
46. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis
47. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
48. Sex hormones (II)
49. Estrogen and the risk of breast cancer
50. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor
51. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer
52. Bone mineral density and risk of breast cancer in older women
53. Guidelines for counseling postmenopausal women about preventive hormone therapy
54. Postmenopausal hormone replacement therapy
55. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
56. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial
57. Phytoestrogen therapy for menopausal symptoms?
58. The effect of raloxifene on risk of breast cancer in postmenopausal women
59. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
60. A prospective study of the incidence of deep-vein thrombosis within a defined urban population
61. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen- receptor-positive tumors
62. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
63. Long term tamoxifen therapy: Can an antagonist become an agonist?
64. Tamoxifen for early breast cancer: An overview of the randomised trials
65. Alendronate and estrogen effects in postmenopausal women with low bone mineral density
66. Hormone replacement therapy and breast cancer mortality in Swedish women: Results after adjustment for "healthy drug-user" effect
67. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
68. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States